Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability. Venetoclax is commonly administered with prophylactic antifungal drugs that may result in drug interactions, of which the underlying mechani...

Full description

Bibliographic Details
Main Authors: Eric D. Eisenmann, Dominique A. Garrison, Zahra Talebi, Yan Jin, Josie A. Silvaroli, Jin-Gyu Kim, Alex Sparreboom, Michael R. Savona, Alice S. Mims, Sharyn D. Baker
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceutics
Subjects:
venetoclax
OATP1B1
antifungal
pharmacokinetics
CYP3A
Online Access:https://www.mdpi.com/1999-4923/14/4/694

Similar Items

Similar Items